About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

J&J Speakers Bio:

Mark Soberman MD, FACS, Senior Safety Officer, Ethicon Global Surgery, Johnson & Johnson

Mark Soberman, MD MBA, FACS is Senior Safety Officer at Ethicon Global Surgery, a Johnson & Johnson company. He received a B.A. in biology from Washington University in St. Louis, M.D. from Emory University School of Medicine and M.B.A from the Darden School of Business at the University of Virginia. He completed his general surgical training at the Emory University Affiliated Hospitals, cardiothoracic surgical residency at George Washington University and an advanced fellowship in general thoracic surgery at the Cleveland Clinic. He has served as Vice-Chair of the Department of Surgery; Director, Section of Thoracic Oncology and Director, Section of Thoracic Surgery at MedStar Washington Hospital Center and as Director, Division of Thoracic
Surgery at Georgetown University Hospital. He has held academic appointments as Associate Professor of Clinical Surgery at Georgetown University School of Medicine and Clinical Assistant Professor of Surgery at George Washington University School of Medicine. He served as Medical Director of the Oncology Service Line and Chief Physician Executive, Monocacy Health Partners at Frederick Regional Health System before joining Ethicon. He has served as President and as a member of the Board of Trustees of the Association of Community Cancer Centers.

Balaji Laxmanan MD, DAABIP is the Senior Director of Clinical Development at the Lung Cancer Initiative (LCI) at Johnson & Johnson. In his role, Balaji is responsible for development and execution of clinical development strategy across LCI programs in the diagnosis and treatment of lung malignancies, with a particular focus on bronchoscopy and medical devices. He received his undergraduate and medical degree from the University of Michigan. He then completed his internal medicine residency at the University of Washington. He remained on faculty at the University of Washington as an Acting Instructor in the Department of Pulmonary and Critical Care Medicine and served as a critical care medicine hospitalist. He then completed fellowships in pulmonary medicine, critical care medicine, and interventional pulmonology at the University of Chicago. He then entered private practice as an interventional pulmonologist in Washington state before joining Johnson & Johnson.
Philippe Szapary MD, MSCE, Clinical Development Head, Lung Cancer Initiative (LCI), Johnson & Johnson

Philippe Szapary, MD, MSCE is Vice President, Clinical Development Head, Lung Cancer Initiative (LCI) at Johnson & Johnson. In this role, Philippe is responsible for the clinical development strategy for both medical devices and novel compounds used as part of diagnostic and treatment strategies for lung malignancies. Prior to this role, Philippe held a number of roles of increasing responsibility in the Immunology Therapeutic area at Janssen having had responsibilities for the development ustekinumab (STELARA®), guselkumab (TREMFYA), golimumab (SIMPONI) and infliximab (REMICADE) in a number of immune mediated diseases in adults and children.

Philippe received his medical degree from the University of Chicago, Pritzker School of Medicine, and completed his training in internal medicine at University of California, San Francisco (UCSF). He later earned a Master of Science degree in Clinical Epidemiology at the University of Pennsylvania School of Medicine. In 1997, he joined the faculty at the University of Pennsylvania in the Department of Medicine where he was active in clinical care, teaching and patient-oriented research for eight years.